LAENNEC Injection 50amp

Description

LAENNEC Injection 50amp is a injectable vitamin preparation from LAENNEC, listed for registered Australian clinics in our Vitamins range. Pack: 50amp. Priced in AUD (A$689.00). Sydney dispatch, nationwide. Not a public treatment clinic. About LAENNEC Injection 50amp Aukoworld IS NOT RESPONSIBLE FOR ANY LOSS OF INCOME AS A RESULT OF NON-DELIVERY LAENNEC  Laennec is the ethical drug manufactured with JBP’s unique technologies. Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards. Warning: As the LAENNEC Injection is an ethical drug, JBP has never sold it on Internet. Ingredients Content Remarks Active ingredient Water-soluble substance of a product of enzymatic human placenta 112 mg Ingredient extracted from human placenta Inactive ingredients Pepsin Trace Gastric mucosal extract Lactose 0.6 mg – pH adjuster q.s. – Description This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one. Indications Improvement of hepatic function in chronic hepatic disease. Dosage and administration The normal adult dose is a 2 ml subcutaneous or intramuscular injection once daily. According to symptoms, the dose can be increased to 2 or 3 times daily. Packaging 2 ml 50 ampoules Cautions for use** 1. Careful Administration LAENNEC should be administrated with care in patients predisposed to allergies. 2. Important Basic Cautions This product is manufactured from the extract of human placenta delivered full-term in Japan. In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV-RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 °C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported. However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection cannot be fully ruled out. 3. Drug Interactions When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported. No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported. Adverse reactions or patients who were suspected to have suffered adverse reactions